The therapeutic effects induced by serotonin-selective reuptake inhibitor (SSRI) antidepressants are initially triggered by blocking the serotonin transporter and rely on long-term adaptations of pre-and post-synaptic receptors. We show here that long-term behavioral and neurogenic SSRI effects are abolished after either genetic or pharmacological inactivation of 5-HT 2B receptors. Conversely, direct agonist stimulation of 5-HT 2B receptors induces an SSRI-like response in behavioral and neurogenic assays. Moreover, the observation that (i) this receptor is expressed by raphe serotonergic neurons, (ii) the SSRI-induced increase in hippocampal extracellular serotonin concentration is strongly reduced in the absence of functional 5-HT 2B receptors and (iii) a selective 5-HT 2B agonist mimics SSRI responses, supports a positive regulation of serotonergic neurons by 5-HT 2B receptors. The 5-HT 2B receptor appears, therefore, to positively modulate serotonergic activity and to be required for the therapeutic actions of SSRIs. Consequently, the 5-HT 2B receptor should be considered as a new tractable target in the combat against depression.
Introduction
The most widely used antidepressants, the serotoninselective reuptake inhibitors (SSRIs), induce an increase in extracellular serotonin (5-hydroxytryptamine, 5-HT) concentrations by acutely blocking the specific serotonin transporter (SERT). 1, 2 The SERT regulates the extracellular serotonin concentration by removing 5-HT from the synaptic cleft, 3 and diverse molecules modulate this activity, including the A 3 adenosine receptor 4 and kinases such as PKG/p38 mitogen-activated protein kinase. 5 Previous studies have suggested a functional interaction between SERT and the 5-HT 2B receptor-a receptor implicated in 5-HT-dependent phenotypes, including impulsivity, aggressivity and suicidality. 6 Ex vivo studies have indicated that 5-HT 2B receptors might participate in the control of SERT in raphe neurons, 7 while in vivo studies further confirmed that 5-HT 2B receptors contribute to the behavioral and physiological effects of the SERT-targeting 5-HT releasers, MDMA (the club-drug ecstasy) and dexfenfluramine. [8] [9] [10] Furthermore, we recently reported that the acute response to SSRIs in the forced swimming test (FST), a classical test for antidepressant activity, is absent in mice lacking 5-HT 2B receptors. 11 Conversely, a 5-HT 2B receptor agonist induced an antidepressant-like action in the FST, suggesting that this receptor is required for acute SSRI effects and might modulate serotonergic tone.
Blockage of SERT and increase of 5-HT levels are immediately attained after SSRI administration, whereas therapeutic effects are only observed after weeks of treatment. The delay before the onset of clinical effects in depressive individuals appears to rely on the time required for stabilization of monoamine levels and other neuroadaptations, including neurogenesis. 12 As well, regulation of 5-HT receptors appears to be required for either the acute or chronic effects of SSRIs, as it was largely demonstrated for 5-HT 1A , 5-HT 2A , 5-HT 2C and 5-HT 4 receptors. [12] [13] [14] [15] [16] Importantly, < 50% of all patients with depression show remission with optimized available antidepressant treatments. 1 Despite extensive research, the neurobiological mechanisms underlying antidepressant effects or the resistance to antidepressants are not yet well understood. 17, 18 Therefore, we studied the chronic actions of SSRIs in behavioral and neurogenic assays, and SSRI-induced alterations in synaptic 5-HT levels in mice with genetic or pharmacological ablation of 5-HT 2B receptors, and demonstrate herein that 5-HT 2B receptors are required for SSRI antidepressant acute and long-term effects, possibly by presynaptic modulation of extracellular 5-HT levels.
Materials and methods

Animals
The 5-HT 2B À/À mice used in all experiments are in a 129S2/SvPas (129S2) background, 19 while SERT
and Pet-1 À/À mice are on C57Bl/6NCrl background. 20, 21 Adult (7-9-week-old) male 5-HT 2B
À/À
, SERT À/À and Pet-1 À/À mice, and their respective wild-type (WT) control mice (originally obtained from Charles River Laboratories, L'Arbresle, France), were derived from heterozygous crosses and were bred at our animal facility. All mice were maintained according to the European Directive directive 86/609/CEE. FST was conducted as already described. 22 The novelty-suppressed feeding (NSF) test was basically conducted as already described, 17 with some modifications (see Supplementary Information).
Chronic treatments, proliferation and survival assays, and tissue preparation For all the drugs employed in this study, the lowest acute effective dose was selected based on our previous data from WT mice.
11 Fluoxetine (3 mg kg À1 per day in 129S2 or 10 mg kg À1 per day intraperitoneal (i.p.) in C57Bl6/6NCrl mice) or vehicle (0.9% NaCl) was injected once daily for 4 weeks. WT mice chronically treated with RS127445 continuously received the 5-HT 2B antagonist at 1 mg kg À1 per day or vehicle (50% dimethyl sulfoxide) via subcutaneous osmotic pumps (Alzets model 2004, L'Arbresle, France) for 4 weeks in addition to the daily i.p. injections of Flx or Veh. The last day of this 4-week experimental protocol, mice received two injections of 150 mg kg À1 5-bromo-2 0 deoxyuridine (BrdU) (2-h interval between injections). Then, 24 h after BrdU administration, a pool of mice was perfused and the brains were recovered for cell proliferation studies. Another pool of mice continued receiving the SSRI or vehicle for 4 more weeks after BrdU administration, and was finally perfused and the brains were recovered for cell survival studies. Similar experimental protocols were conducted for cell proliferation induced by paroxetine (2 mg kg À1 ) or BW723C86 (3 mg kg À1 per day in 129S2 or 10 mg kg À1 per day i.p. in C57Bl6/6NCrl mice). All these drugs were injected once daily, and at the end of the chronic treatments (24 h and 4 weeks after BrdU, respectively, for proliferation and survival assays), mice were anesthetized and their brains were removed, fixed and processed for immunohistochemistry. See Supplementary Information.
Immunohistochemistry and immunofluorescence
Newborn cells were detected by classical peroxidase immunostaining of BrdU, an exogenous marker of cell division, or Ki67, an endogenous cell cycle marker. Identification of newly formed cells was performed by double-labeling cells with neuronal or astroglial markers and BrdU or Ki67, followed by confocal microscopy (see Supplementary Information).
Microdialysis in freely moving mice
Microdialysis and high-pressure liquid chromatography were performed as already published by our laboratory. [8] [9] [10] All measurements were obtained from freely moving mice following injections of RS127445 (0.5 mg kg À1 , i.p.) and/or paroxetine (2 mg kg À1 , i.p.) (see supplementary Information).
Single-cell RT-PCR Pet-1-EGFP mice, generated from a cross of Pet-1-CRE 23 with RCE:loxP 24 mice, were used for single-cell reverse-transcription (RT)-PCR experiments. Mice were anesthetized and decapitated, and the brain was rapidly dissected out. Coronal slices (250 m thick) were prepared using a vibratome in artificial cerebral spinal fluid supplemented with sucrose. The methodology involving harvesting of cytoplasmic content and subsequent single-cell PCR amplification has been described elsewhere. 25 5-HT 1A receptor quantitative PCR Raphe nucleus and hippocampus were dissected and homogenized in 1 ml of RNAsolv. Genomic DNA was removed by digestion with Amplification Grade DNase I (Sigma-Aldrich, St Quentin Falavier, France). First-strand cDNA was synthesized by reverse transcription of 3 mg of total RNA with Superscript-II reverse transcriptase (Invitrogen, Illkirch, France) according to standard protocols. Reverse transcriptase was omitted in some samples as negative control. Relative expression levels of 5-HT 1A mRNA were determined by real time RT-PCR using Absolute SYBR Green Mix (ABgene, Illkirch, France) and a set of primers specific for 5-HT 1A receptor. 5-HT 1A expression was normalized to mouse CyclophilinB mRNA expression. Data were analyzed with the 2-DCt method, and values are expressed as the mean of four separate experiments performed in duplicate.
In situ hybridization Coronal sections from the same experimental subjects used in immunohistochemistry studies were employed for in situ hybridization, which was performed as previously described 26 on a pool of two coronal free-floating sections per mouse from each experimental group (WT-Veh; WT-Flx; 5-HT 2B À/À -Veh and 5-HT 2B À/À -Flx). 5-HT 1A (IMAGE:8861702) dig-UTPlabeled probe was used and detected using an antibody coupled to alkaline phosphatase (1/2000, Roche, Meylan, France). Alkaline phosphatase activity was revealed using 4-nitroblue tetrazolium chloride/ 5-bromo 4-chloro 3-indolyl phosphate.
8-OH-DPAT-induced hypothermia
Body temperature was measured intrarectally using a lubricated probe inserted B2 cm and a digital thermometer (CEM advanced thermometer; DT-610B). 27 Mice were moved to the behavioral room and two baseline temperature measurements were taken. After 10 min, animals received 8-hydroxy-2-(di-n-propylamino)-tetraline (8-OH-DPAT) 0.5 mg kg À1 , i.p., and body temperature was recorded every 15 min for a total of 45 min.
Statistical analysis
To determine differences between the experimental groups, responses were analyzed by either an unpaired Student's t test or a two-way analysis of variance with genotypes and treatments as main factors, depending on the experimental design. Previously, normal distributions and homoscedasticity were verified by Shapiro-Wilk's test and Levene's test, respectively. Bonferroni's or Dunnett's test was used for post hoc comparisons. The 5-HT extracellular levels and hypothermic responses in both genotypes were compared by two-way repeated measures analysis of variance. In all cases, P < 0.05 was considered statistically significant. A summary of tests employed and statistics are presented in Supplementary Table S1 .
Results
Statistical analyses of the data are summarized in Supplementary Table S1 .
5-HT 2B receptors in the chronic behavioral effects of SSRIs
Although the FST remains a key screen for acute antidepressant activity with good reliability and predictive validity, this test cannot reveal the neurobiological mechanisms underlying antidepressant therapeutic effects that are only observed after weeks of treatment. We thus studied the putative participation of 5-HT 2B receptors in chronic behavioral effects triggered by SSRIs using the NSF test, one of the few behavioral tests sensitive to chronic antidepressant treatments. Consistent with the impulsive phenotype shown by 5-HT 2B À/À mice, 6 their basal latency to feed in the NSF test was decreased compared with WT mice (Figures 1a and b) . To ensure that 5-HT 2B À/À mice are able to respond in this test, we injected the anxiolytic drug diazepam and observed a further decrease in the latency to feed (Figure 1a) . Then, we chronically treated WT and 5-HT 2B À/À mice with either Flx or Prx for 4 weeks and conducted an NSF test. Interestingly, even though Flx and Prx chronic treatments significantly reduced the latency to feed in WT mice, no differences were observed between control and SSRItreated 5-HT 2B À/À mice ( Figure 1b ). These mutant mice also failed to respond in the NSF after injections of 1 or 20 mg kg À1 Flx (Supplementary Figure S1a) . To eliminate putative bias in the NSF test, food intake in the home cage was measured during the 15 min immediately following the NSF test. No significant changes were registered according to either genotype or treatment (Supplementary Figure S1b) .
To verify that the results obtained in 5-HT 2B À/À mice were not due to developmental alterations, we also tested a group of WT mice after simultaneous chronic (Figure 1c ), including the reduced basal latency and the lack of SSRI-antidepressant action.
As acute injection of BW723C86 mimicked the effect of SSRIs in WT mice in the FST, 11 we tested the effect of chronic direct activation of 5-HT 2B receptors. A 4-week treatment with BW723C86 induced a significant decrease in the latency to feed in WT mice, with no effect on 5-HT 2B À/À mice (Figure 1d ). Thus, direct chronic activation of 5-HT 2B receptors appears sufficient to induce chronic SSRI-like effects in the NSF test.
Pro-neurogenic and plastic effects induced by SSRIs
The well-established neurogenic effect of chronic antidepressant treatment 28 has been proposed to be necessary for behavioral responses to SSRIs. 17 Therefore, cell proliferation and survival were studied in mice in which 5-HT 2B receptors were genetically or pharmacologically abolished. Chronic administration of either Flx or Prx failed to induce a significant increase in the incorporation of the exogenous DNA tracer, BrdU, in the hippocampal subgranular zone in 5-HT 2B À/À mice, whereas an SSRI neurogenic effect was clearly observed in WT mice (Figure 2a) . These results were confirmed by the endogenous cell cycle progression marker Ki-67 (Supplementary Figure  S2a) . Also, no alterations in cell proliferation in either WT or mutant mice were observed in the subventricular zone, confirming that the neurogenic effect of SSRIs is specific to the hippocampal subgranular zone of the dentate gyrus (Supplementary Figure S2b) . Moreover, chronic Flx did not increase cell proliferation in WT mice following chronic pharmacological inactivation of 5-HT 2B receptors (Figure 2b ). Altogether, these results confirm that a lack of functional 5-HT 2B receptors is sufficient to abolish the chronic actions of SSRIs at the cellular level.
Again, as in behavioral tests, chronic treatment with the 5-HT 2B receptor agonist BW723C86 induced an antidepressant-like action only in WT mice, evidenced by a significant increase in BrdU incorporation (Figure 2c) . We verified that the chronic cellular effects of SSRIs are mediated by SERT and not by direct action at 5-HT 2B receptors, as suggested by a previous study 29 in spite of the low affinity of Flx for mouse 5-HT 2B receptors (Ki = 5.65 ± 0.52). 10 After a 4-week treatment with Flx, SERT À/À mice did not show any increase in cell proliferation (Supplementary Figure S2c) , confirming that the observed Flx effects in WT mice depend on SERT.
Cell survival was also analyzed after administration of Flx for 8 weeks (BrdU was injected after the first 4 weeks), and a significant increase, dependent on the maintenance of Flx, was only observed in WT but not in 5-HT 2B À/À mice (Figure 2d ). Regarding the fate of these newly generated cells, colabeling of BrdU with neuronal and astroglial markers was conducted in proliferation (24 h after BrdU) and survival (4 weeks after BrdU) conditions, and no difference in cell differentiation was found between genotypes (Supplementary Figure S3 ).
5-HT 2B receptors are required for SSRI-induced extracellular 5-HT accumulation
Although the neurobiological mechanisms mediating the behavioral and neurogenic effects of SSRIs are not completely understood, it is clear that responses to SSRIs do not occur after 5-HT depletion. 30 We therefore evaluated extracellular hippocampal 5-HT levels, by means of microdialysis assays, after acute administration of SSRIs to freely moving mice. In WT mice, a single administration of Prx induced a maximal increase in 5-HT concentrations 60 min after injection, and levels remained elevated for at least 2 h (Figure 3a) . In 5-HT 2B À/À mice, as in RS127445-pretreated WT mice, the maximal increase in 5-HT concentrations following a single Prx injection was significantly lower (around a quarter of the increase Figure S4a) , consistent with the lack of major alterations in tissue 5-HT levels in 5-HT 2B À/À or chronically RS127445-treated WT mice after Flx treatment (Supplementary Figure S4b) . Moreover, SERT-binding parameters as well as raphe and hippocampus SERT protein expression were similar in either genotype (Supplementary Figures S4c, d) .
To reinforce the hypothesis that 5-HT 2B receptors directly participate in the control of 5-HT levels, we then evaluated 5-HT 2B receptor expression in raphe serotonergic neurons. We performed single-cell RT-PCR experiments on selected green fluorescent protein -positive dorsal and median raphe neurons from Pet-1-EGFP mice (Pet-1 is a transcription factor specific for 5-HT neurons, and Pet-1-EGFP mice express EGFP only in 5-HT-positive neurons). 23 Among the Pet-1-positive neurons, a large majority of the Tph2 (the limiting enzyme in 5-HT synthesis)-expressing cells also expressed 5-HT 2B receptor mRNA (n = 10 out of 12 neurons) (Figure 3b ), establishing for the first time the expression of this receptor in raphe serotonergic neurons.
Nevertheless, these experiments cannot exclude a contribution to antidepressant effects from potential postsynaptic 5-HT 2B receptors expressed on nonserotonergic neurons. We thus re-evaluated the acute Flx and BW723C86 effects in two different animal models in which presynaptic serotonergic components are altered: Pet-1 À mice, in which 5-HT neurons do not differentiate and 5-HT levels are reduced by 80%, 21 and SERT À/À mice, in which 5-HT neurons do not uptake 5-HT 20 and thus, 5-HT storage is decreased. 31 Neither of these groups of mice responded to acute Flx or BW723C86 stimulation in the FST (Figures 3c and d) . After a 4-week treatment with the 5-HT 2B receptor agonist, SERT À/À mice did not show any increase in cell proliferation (Supplementary Figure S2d) . Thus, as Flx, the efficacy of BW723C86 requires both SERT and serotonergic neurons-results that are consistent with a presynaptic role for the 5-HT 2B receptor.
5-HT 1A receptors are not altered by the absence of 5-HT 2B receptors
The 5-HT 1A autoreceptor is involved in chronic SSRI effects. 17, 32 The proposed mechanism for SSRI action is a temporary increase in serotonergic tone that downregulates presynaptic 5-HT 1A expression. 12, 33 We wondered whether the absence of 5-HT 2B receptors could modify expression and/or functionality of 5-HT 1A receptors. Raphe nuclei or hippocampal basal expression of 5-HT 1A receptors in 5-HT 2B À/À mice-as evaluated by quantitative PCR, binding assays and in situ hybridization-was not different from WT mice (Figures 4a-c) . Moreover, we evaluated the functionality of these receptors by two different tests. Acute administration of the 5-HT 1A agonist 8-OH-DPAT induces a decrease in body temperature that is mediated by presynaptic 5-HT 1A receptors. 27 Mice from both genotypes showed a similar hypothermic response after an acute administration of 8-OH-DPAT at 0.5 mg kg À1 , i.p. (Figure 4d ). In addition, the response in the FST to 8-OH-DAT is mediated by postsynaptic receptors, and at higher doses of this 5-HT 1A agonist, mice develop a serotonin syndrome. Again, for this test, mice from both genotypes had similar responses (Figure 4e) , indicating no differences in functionality for this receptor. Therefore, the lack of extracellular 5-HT accumulation, behavioral or neurogenic responses after SSRI treatment in 5-HT 2B À/À mice cannot be explained by alterations in 5-HT 1A receptor expression or functionality.
Discussion
Based on the results presented herein, the activation of 5-HT 2B receptors is necessary for acute and chronic SSRI actions, and chronic stimulation with a 5-HT 2B receptor agonist is sufficient to mimic SSRI effects in WT mice. Furthermore, the moderate increase in extracellular 5-HT levels induced by SSRIs in the absence of functional 5-HT 2B receptors might be insufficient to trigger behavioral and neurogenic actions. These data, together with the single-cell RT-PCR results showing expression of 5-HT 2B receptors in raphe serotonergic neurons, are consistent with a presynaptic action of 5-HT 2B receptors mediating the acute and chronic SSRI effects.
Although many data have been published on the topic, the exact role of hippocampal neurogenesis in the clinical response to antidepressants remains equivocal. 18, 34 Neuroplastic adaptations induced by chronic antidepressants appear to result from slow and fine regulations allowing a re-establishment of monoamine levels 35 and 5-HT receptor adaptation. 12 In this context, considering the strong reduction in the SSRI-induced increase in extracellular 5-HT both in 5-HT 2B À/À mice and RS127445-treated WT mice, the lack of SSRI-induced proliferative and survival effects in these mutant animals is not unexpected. The neurogenic actions of antidepressants have been proposed to be responsible for the behavioral effects induced by chronic treatment. 17 Accordingly, our results show that the absence of neurogenic effects induced by chronic SSRIs in mice with pharmacologically or genetically abolished 5-HT 2B receptors correlates with a lack of a response in the NSF test. Conversely, chronic agonist stimulation of the 5-HT 2B receptor is associated with neurogenic effects and a positive response in the NSF test, supporting a link between neurogenesis and behavior.
Previous studies from our laboratory demonstrate that the absence of 5-HT 2B receptors impairs the response to drugs targeting the 5-HT system. In particular, 5-HT 2B receptors are necessary for the 5-HT-releasing effect of SERT-targeting drugs, like MDMA (the club-drug ecstasy) and dexfenfluramine. [8] [9] [10] In line with these results, we shown here that acute SSRI administration to 5-HT 2B À/À mice induces also a reduced (1/4) increase in hippocampal 5-HT levels compared with WT mice. Furthermore, we demonstrate for the first time that 5-HT 2B receptors are expressed by serotonergic neurons of the raphe nuclei, which is consistent with a positive regulatory role for these receptors in synaptic 5-HT homeostasis. This inhibition of SSRI-induced extracellular 5-HT accumulation in mice with no functional 5-HT 2B receptors likely reflects a lack of positive control exerted by 5-HT signaling in raphe neurons. Indeed, in vivo microdialysis experiments performed with the agonist BW723C86 confirm that local 5-HT 2B receptor activation in the raphe nuclei is sufficient to induce extracellular 5-HT accumulation. 9 Moreover, stimulation of 5-HT 2B receptors appears to be presynaptic as BW723C86-induced acute behavioral effects are abolished in Pet-1 À mice (a genetic model of 5-HT depletion) or in SERT À/À mice. Together, these data identify, for the first time, 5-HT 2B receptors as possible positive 5-HT autoreceptors, acting in an opposing manner to the 5-HT 1A and 5-HT 1B receptors, which are well established as negative autoreceptors. 36 This concept is consistent with previous electrophysiology studies showing reduced or abolished 5-HT-dependent depolarization of serotonergic neurons by 5-HT 2 receptor antagonists (ketanserin or mesulergine) in the presence of the 5-HT 1A receptor antagonist (WAY100635), 37 but extensive electrophysiological studies are required to fully test this hypothesis. Moreover, given that no specific anti-mouse 5-HT 2B receptor antibody is currently available (each giving different results as well as residual labeling in 5-HT 2B À/À mice), we are not currently able to evaluate whether these autoreceptors are localized presynaptically or in the soma of the raphe serotonergic neurons. This last point could have important physiological consequences in the mode of action of the receptor.
A similar lack of acute and chronic effects were obtained in mice in which the 5-HT 2B receptor was pharmacologically blocked or genetically ablated, confirming that effects seen in mutant mice are not a consequence of developmental compensation. Notably, the baseline response in the NSF test is altered in both groups of mice and might result from specific settings established as a consequence of chronically inactive 5-HT 2B receptors. The SSRIreduced latency to feed in the NSF is associated with anxiolytic-like effects. The ability of 5-HT 2B À/À mice to show anxiolysis clearly persists, as evidenced by their response to diazepam. The fact that both 5-HT 2B receptor agonist and antagonist induced a similar decrease in the latency to feed appears paradoxical. Nevertheless, all the results obtained herein for BW723C86 are consistent with antidepressant-like actions, whereas the response induced in the NSF test by RS127445 may be a consequence of the impulsive phenotype already described for these animals 6 rather than an anxiolytic effect. Moreover, the fact that basal neurogenesis is unaltered in either WT mice chronically treated with RS127445 or in 5-HT 2B À/À mice is more consistent with an effect of impulsivity in the NSF in mice with non functional 5-HT 2B receptors than an antidepressant-like action.
The recent report that a single-nucleotide polymorphism introducing a stop codon at the beginning of the human 5-HT 2B receptor (Q20*) is associated with psychiatric diseases marked by high impulsivity and suicidal behavior 6 supports a possible action of 5-HT 2B receptors on serotonergic tone. Herein, we show that the presence of a functional 5-HT 2B receptor is required for behavioral and neurogenic SSRI actions. One of the unanswered questions about antidepressant effects that remains is the lack of explanation for the limited percentage of patients responding to chronic treatment. 1 Interindividual variation in antidepressant efficacy is thought to be at least partly genetic. A number of studies have tested the association between allelic variations in candidate genes of the serotonergic pathway involved in the synthesis, transport, recognition or degradation of 5-HT and the response to various SSRIs. However, even in positive studies (that is, long/short alleles in the SLC6A4/SERT promoter), 38 these polymorphisms do not explain all of the variance seen in clinical responses, suggesting the involvement of variants within other genes. To date, none of these studies investigated the potential role of the 5-HT 2B receptor. We believe that our data pinpoint the need to investigate the association between treatment response to SSRIs and single-nucleotide polymorphisms in the 5-HT 2B receptor gene. Interestingly, 70% of the Q*20 male cases displayed impulsive suicidal behavior, and 66% had at least one life-threatening suicide attempt by age 33.5. 6 Thus, it would be interesting to collect and analyze clinical data related to SSRI responses from these cases. Moreover, 5-HT 2B -receptor-mutant mice appear to be a useful animal model for studying the clinical resistance to SSRI antidepressant effects.
The contribution of 5-HT 2B receptors to the effects of SSRI antidepressants is undoubtedly demonstrated by the results presented above, and agonist stimulation of this receptor induces SSRI-like effects. However, it is clear that 5-HT 2B receptor agonists cannot be used as antidepressant molecules, given established harmful cardiopulmonary peripheral effects of such compounds. 39, 40 Despite notable advances, many patients with anxiety/depressive disorders fail to adequately respond to existing pharmacological treatments. Augmenting antidepressant efficacy with other drugs has generated considerable clinical interest. Our study demonstrating that behavioral and neurogenic SSRI effects are abolished after pharmacological inactivation of 5-HT 2B receptors should be taken into account when designing polypharmacology treatment strategies, given that actions mediated by this receptor might hinder the desired effects. As novel antidepressants are being developed to both ameliorate efficacy of treatments and increase the number of responders, the positive contribution of the 5-HT 2B receptor to serotonergic homeostasis should be considered.
